Figure 4.

Murlentamab opsonization of SKOV3-R2⁺ activates an effective anti-tumor T cell immune response. SKOV3-R2⁺ ovarian tumor cells were labeled with different 3C23K antibodies (3C23K-FcKO control, 3C23K-CHO normally fucosylated or murlentamab the low fucosylated form) and cultured in the presence of human monocyte-derived macrophages from healthy donors unstimulated (M0) or stimulated with M-CSF and IL-10 (TAMs). After 3 days of co-culture, activated T cells coming from the same healthy donor were added in the culture well for 4 more days. (A) The CD4⁺ Th1/Th2 polarization profile, (B) the proportion of CD3⁺ CD4⁺ CD25⁺ regulatory T cells and (C) the activation of T CD8⁺ cells were determined by flow cytometry after four days of co-culture. Data shown (boxplots) are the results from two different experiments (performed with two different healthy donors). * p < 0.05; ** p < 0.01; *** p < 0.001. p values were determined using one-way ANOVA analysis followed by Tukey’s multiple comparisons test.